Advertisement
Screener

IQVIA HOLDINGS INC. (IQV) Overview

IQVIA HOLDINGS INC. (IQV) Overview

  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 1.61; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 1.93; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 1.54; Beat / miss (m).
  • 1 Jan 2025: Period ending 31 Mar 2025; Estimate (m); Actual 1.40; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$148.83$169.94$194.05$221.58$253.02$288.922025-11-062026-11-06$130.15$153.47$180.97$213.40$251.65$296.742021-11-082026-11-06$69.35$92.75$124.04$165.90$221.88$296.742016-11-072026-11-06$39.50$59.12$88.49$132.46$198.25$296.742013-05-092026-11-06$39.50$59.12$88.49$132.46$198.25$296.742013-05-092026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$271.73
Previous close
$268.99
Change
$2.74
Change (%)
1.02%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

IQV
+19.39%
S&P 500
(m)

1 year

IQV
+48.92%
S&P 500
(m)

3 years

IQV
+36.79%
S&P 500
(m)

5 years

IQV
+10.79%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

31 Mar 2026 ○ Estimate (m) ● Actual 1.61

1.321.521.711.912.1130 Sept 2024: estimate (m); actual 1.5530 Sept 2024(m)31 Mar 2025: estimate (m); actual 1.4031 Mar 2025(m)30 Jun 2025: estimate (m); actual 1.5430 Jun 2025(m)30 Sept 2025: estimate (m); actual 1.9330 Sept 2025(m)31 Mar 2026: estimate (m); actual 1.6131 Mar 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202631 Mar 2026(m)1.61(m)(m)
1 Jul 202530 Sept 2025(m)1.93(m)(m)
1 Apr 202530 Jun 2025(m)1.54(m)(m)
1 Jan 202531 Mar 2025(m)1.40(m)(m)
1 Jul 202430 Sept 2024(m)1.55(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 7.84

4.875.666.457.238.0231 Dec 2021: estimate (m); actual 4.9531 Dec 2021(m)31 Dec 2022: estimate (m); actual 5.7231 Dec 2022(m)31 Dec 2023: estimate (m); actual 7.2931 Dec 2023(m)31 Dec 2024: estimate (m); actual 7.4931 Dec 2024(m)31 Dec 2025: estimate (m); actual 7.8431 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)7.84(m)(m)
1 Jan 202431 Dec 2024(m)7.49(m)(m)
1 Jan 202331 Dec 2023(m)7.29(m)(m)
1 Jan 202231 Dec 2022(m)5.72(m)(m)
1 Jan 202131 Dec 2021(m)4.95(m)(m)

Revenue vs. Earnings

USD

31 Mar 2026 ■ Revenue 4.15B ■ Earnings 0.27B — Profit margin 6.60%

-0.52B5.6%1.28B8.0%3.08B10.4%4.89B12.8%30 Jun 2025: revenue 4.02B; earnings 0.27B; profit margin 6.62%30 Jun 202530 Sept 2025: revenue 4.10B; earnings 0.33B; profit margin 8.07%30 Sept 202531 Dec 2025: revenue 4.36B*; earnings 0.51B*; profit margin 11.78%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 4.15B; earnings 0.27B; profit margin 6.60%31 Mar 2026

31 Dec 2025 ■ Revenue 16.31B ■ Earnings 1.36B — Profit margin 8.34%

-1.96B6.6%4.78B7.7%11.53B8.9%18.27B10.1%31 Dec 2022: revenue 14.41B; earnings 1.09B; profit margin 7.57%31 Dec 202231 Dec 2023: revenue 14.98B; earnings 1.36B; profit margin 9.06%31 Dec 202331 Dec 2024: revenue 15.40B; earnings 1.37B; profit margin 8.91%31 Dec 202431 Dec 2025: revenue 16.31B; earnings 1.36B; profit margin 8.34%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$271.73(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$271.73High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning IQV

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 31 Mar 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$1.39B
Profit margin
8.33%
Return on assets · 12 month
4.86%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
93.00K
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.61M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-0.36%*
Total return · month
2.87%*
Total return · quarter
39.24%*
Total return · half year
64.25%*
Total return · year to date
19.39%*
Total return · 1 year
48.92%*
Total return · 3 years
36.79%*
Total return · 5 years
10.79%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$16.63B
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
254.51%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

IQVIA HOLDINGS INC. Overview

View more →

(m)

(m)

SEC CIK
1478242
Industry (SIC)
8731 Services-Commercial Physical & Biological Research
Country of operation
United States
Business address
2400 ELLIS ROAD, DURHAM, North Carolina, 27703, United States
Fiscal year end
1231
Phone
919-998-2000

Similar stocks

Stock NameCountryMarket CapPE Ratio
INCYTE CORP (INCY)United States$24.855B13.14
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B